MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
Mesenbio is advancing a new generation of EV therapeutics powered by FT-01, our proprietary, immortalised mesenchymal stem cell line. FT-01 delivers consistent, scalable EV production, solving one of the field’s biggest barriers and enabling clinical-grade manufacturing for regenerative and targeted therapies.
Their platform-first strategy focuses on establishing FT-01 as the go-to production platform for EV-based therapeutics, while validating its therapeutic potential through MEV-N01, their proof-of-concept program for rheumatoid arthritis (RA).
Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.